163 related articles for article (PubMed ID: 18632222)
1. Loss of heterozygosity in the RAD51 and BRCA2 regions in breast cancer.
Nowacka-Zawisza M; Bryś M; Romanowicz-Makowska H; Kulig A; Krajewska WM
Cancer Detect Prev; 2008; 32(2):144-8. PubMed ID: 18632222
[TBL] [Abstract][Full Text] [Related]
2. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
[TBL] [Abstract][Full Text] [Related]
3. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
Nowacka-Zawisza M; Brys M; Romanowicz-Makowska H; Kulig A; Krajewska WM
Pathol Int; 2008 May; 58(5):275-81. PubMed ID: 18429825
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.
Nowacka-Zawisza M; Forma E; Walczak M; Różański W; Bryś M; Krajewska WM
Med Oncol; 2015 Nov; 32(11):246. PubMed ID: 26433958
[TBL] [Abstract][Full Text] [Related]
5. Genetic instability in the RAD51 and BRCA1 regions in breast cancer.
Nowacka-Zawisza M; Bryś M; Romanowicz-Makowska H; Kulig A; Krajewska WM
Cell Mol Biol Lett; 2007; 12(2):192-205. PubMed ID: 17180310
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Silva JM; Gonzalez R; Provencio M; Dominguez G; Garcia JM; Gallego I; Palacios J; España P; Bonilla F
Breast Cancer Res Treat; 1999 Jan; 53(1):9-17. PubMed ID: 10206068
[TBL] [Abstract][Full Text] [Related]
7. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.
Hampl JA; Hampl M; Reiss G; Koch R; Saeger HD; Schackert HK
Anticancer Res; 2004; 24(1):281-90. PubMed ID: 15015609
[TBL] [Abstract][Full Text] [Related]
8. Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas.
Leighton X; Srikantan V; Pollard HB; Sukumar S; Srivastava M
Cancer Lett; 2004 Jul; 210(2):239-44. PubMed ID: 15183540
[TBL] [Abstract][Full Text] [Related]
9. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
10. [Loss of heterozygosity on chromosome 3p in breast cancer and precancerous lesion].
Tang XL; Yao GY; Chen LR; Yang ZR; Li SL
Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1314-7. PubMed ID: 17217815
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity and microsatellite instability at RAD52 and RAD54 loci in breast cancer.
Nowacka-Zawisza M; Bryś M; Hanna RM; Zadrozny M; Kulig A; Krajewska WM
Pol J Pathol; 2006; 57(2):83-9. PubMed ID: 17019970
[TBL] [Abstract][Full Text] [Related]
12. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
Söderlund K; Skoog L; Fornander T; Askmalm MS
Radiother Oncol; 2007 Sep; 84(3):242-51. PubMed ID: 17707537
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A
Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer.
Caldés T; Perez-Segura P; Tosar A; de La Hoya M; Diaz-Rubio E
Teratog Carcinog Mutagen; 2000; 20(5):283-91. PubMed ID: 10992275
[TBL] [Abstract][Full Text] [Related]
15. [Association of polymorphisms of N372H in BRCA2 gene and 135G/C in RAD51 gene and breast cancers].
Hu R; Wei Y; Jiang WJ; Yao WX; Long QM; Zhang JH; Liang Y; Tang XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Nov; 39(6):973-5. PubMed ID: 19253839
[TBL] [Abstract][Full Text] [Related]
16. Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors.
Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Koutroumbi E; Markopoulos C; Gogas J; Kittas C
Anticancer Res; 2001; 21(2A):991-9. PubMed ID: 11396193
[TBL] [Abstract][Full Text] [Related]
17. High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity.
Yang TL; Su YR; Huang CS; Yu JC; Lo YL; Wu PE; Shen CY
Genes Chromosomes Cancer; 2004 Nov; 41(3):250-6. PubMed ID: 15334548
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic analysis of the BRCA2 tumor suppressor gene region in cutaneous squamous cell carcinomas.
Gray SE; Kay E; Leader M; Mabruk M
J Cutan Pathol; 2008 Jan; 35(1):1-9. PubMed ID: 18095987
[TBL] [Abstract][Full Text] [Related]
19. Lack of association between LOH in the 9p region and clinicopathologic parameters in primary breast cancer.
Vieira de Oliveira SF; Oliveira MM; Urban CA; de Lima RS; Cavalli IJ; Ribeiro EM
Cancer Genet Cytogenet; 2010 Jul; 200(1):23-7. PubMed ID: 20513530
[TBL] [Abstract][Full Text] [Related]
20. High frequency of somatic missense mutation of BRCA2 in female breast cancer from Taiwan.
Chen FM; Hou MF; Chang MY; Wang JY; Hsieh JS; Ou-Yang F; Huang TJ; Lin SR
Cancer Lett; 2005 Apr; 220(2):177-84. PubMed ID: 15766593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
